转移灶切除术术后索拉非尼对比观察治疗转移性透明细胞肾细胞癌:RESORT随机II期研究结果
RESORT研究是一项多中心随机开放标签II期试验,纳入69例既往行肾切除术并接受根治性转移灶切除术(≤3个病灶)的透明细胞转移性肾细胞癌患者,1:1随机接受索拉非尼(标准剂量400mg每日两次)或观察,最长52周。主要终点无复发生存期(RFS)在两组间无显著差异(中位RFS观察组37个月 vs 索拉非尼组21个月,log-rank p=0.404)。索拉非尼组任何级别不良事件发生率84%、≥3级22%,因不良事件停药率19%。
要点
- 转移灶切除术后索拉非尼未改善无复发生存期(中位37 vs 21个月,p=0.404)。
- 索拉非尼组任何级别不良事件84%、≥3级22%,因不良事件停药率19%。
- 对≤3个转移灶的透明细胞mRCC,术后观察仍是可选策略。
核心结论
- 在转移性透明细胞肾细胞癌患者接受根治性转移灶切除术后,索拉非尼全身治疗相比单纯观察未增加无复发生存期。
研究设计与样本
- RESORT为多中心、随机、开放标签、II期研究,2012年11月至2017年11月在意大利开展。
- 纳入既往行肾切除术并接受根治性转移灶切除术(≤3个病灶)的透明细胞转移性肾细胞癌患者,转移灶切除术后12周内1:1随机。
- 共筛查76例,随机69例:索拉非尼组33例,观察组36例;索拉非尼标准剂量400mg每日两次,最长52周。
- 分层因素为距肾切除术时间、转移部位和病灶数目;主要终点为无复发生存期(RFS)。
主要发现
- 中位随访38个月,观察组中位RFS为37个月(95%CI 20-NA),索拉非尼组为21个月(95%CI 11-NA),log-rank检验p=0.404。
- 观察组 vs 索拉非尼组12、24、36个月RFS概率分别为74% vs 63%、59% vs 49%、50% vs 41%。
- 索拉非尼组任何级别不良事件发生率84%,观察组31%;≥3级不良事件分别为22%和3%。
- 索拉非尼组因不良事件治疗中断率为19%。
临床怎么用
- 对于转移灶数目≤3个的透明细胞转移性肾细胞癌,根治性转移灶切除术后可考虑观察而非常规索拉非尼辅助治疗。
- 术后索拉非尼治疗需权衡毒性:≥3级不良事件22%、因不良事件停药19%。
局限性
- 本研究为II期随机开放标签研究,样本量较小(共69例随机),可能影响统计效能。
- 中位RFS的95%CI上限不可评估(NA),随访38个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In selected metastatic renal cell carcinoma (mRCC) patients, radical metastasectomy followed by observation is a potential strategy. It is still to be defined whether systemic therapy should be administered following metastasectomy. OBJECTIVE: To assess the potential benefit of postoperative treatment with sorafenib compared with observation alone after radical metastasectomy in mRCC patients. DESIGN, SETTING, AND PARTICIPANTS: The RESORT trial was a multicenter, randomized, open-label, phase 2 study conducted between November 2012 and November 2017 in Italy. Patients with clear-cell mRCC pretreated with nephrectomy and undergoing radical metastasectomy (three or fewer lesions) were eligible for the study. Patients were randomized (1:1) within 12 wk from metastasectomy to sorafenib (standard dose 400 mg twice daily) or observation for a maximum of 52 wk. Stratification factors were interval from nephrectomy, site, and number of lesions. Overall, 76 patients were screened and 69 were randomized: 33 were assigned to sorafenib and 36 to observation. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints were overall survival and the safety profile. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: RFS curves were estimated with the Kaplan-Meier method, and the log-rank test was used to statistically compare the curves. RESULTS AND LIMITATIONS: At a median follow-up of 38 mo, median RFS was 37 mo (95% confidence interval [CI] 20-not available [NA]) in the observation arm versus 21 mo (95% CI 11-NA) in the sorafenib arm (log-rank test p = 0.404), with 12-, 24-, and 36-mo RFS probability of 74% versus 63%, 59% versus 49%, and 50% versus 41%, respectively, in the observation versus the sorafenib arm. Any-grade adverse event (AE) rates were 84% in the sorafenib arm and 31% in the observation arm; grade ≥3 AE rates were 22% and 3% in the sorafenib and the observation arm, respectively, with a rate of treatment discontinuation for AEs of 19% in the sorafenib arm. CONCLUSIONS: This prospective study showed that systemic treatment with sorafenib did not increase RFS as compared with observation in mRCC patients following radical metastasectomy. PATIENT SUMMARY: This article reports the clinical outcome of patients with metastatic renal cell carcinoma treated with sorafenib or managed with an observation-alone strategy after the radical surgery of metastases. We found that sorafenib did not improve the patient outcome in terms of relapse-free survival in this selected population.
引用
- Procopio G, Apollonio G, Cognetti F, et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol. 2019. PMID: 31542243. doi:10.1016/j.euo.2019.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。